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Abstract Inhaled corticosteroids reduce airway inflammation and bronchial hyper-responsiveness in asthma. Their 
regular use is associated with a reduction in morbidity and mortality from asthma. International guidelines recommend 
their use as first-line treatment in asthma and the dose should be increased stepwise in accordance with asthma severity 
Short-acting Pz-agonists are recommended for use as reliever medication for the acute relief of symptoms. Long-acting 
b2-agonists have a sustained bronchodilator action but are not recommended for use as monotherapy in asthma, particu- 
larly because they laclc clinically relevant anti-inflammatory action.The seminal observation in a controlled trial that the 
addition of salmeterol to low-dose inhaled beclomethasone dipropionate was superior to doubling the dose ofthe be- 
clomethasone dipropionate was followed by several well-controlled studies that confirmed this observationThese in- 
cluded multinational and multicentre trials in large numbers of patients and the use of different inhaled corticosteroids 
and the two long-acting Pl-agonists, formoterol and salmeterol.Therefore level Aevidence (randomized controlled trials 
with a rich body ofevidence) is available for this recommendation. Based on this, updated asthma guidelines recommend 
the addition of long-acting /&agonists for chronic asthmathat is at least moderately severe or mild asthmathat is not well 
controlled with low-dose inhaled corticosteroids. Attention was therefore focused on developing combination inhalers 
that included inhaled corticosteroids and long-acting /Il-agonists in order to simplify asthma treatment and improve 
adherence to prescribed medication. Symbicort @ Turbuhaler@ (budesonide/formoterol in a single inhaler) is one such 
development. Studies to date in over 800 adult patients have confirmed that budesonide/formoteroI is superior to double 
the dose of budesonide monotherapy and at least as effective and safe as budesonide and formoterol in separate inhalers. 
These studies also demonstrate thatthere are no physico-chemical interactionswhen thetwo medications are combined 
in a single inhaler. Symbicort @in its easy to use formulation and inhaler device represents avaluable addition tothe phar- 
macological management of asthma. 
0 2002 Elsevier Science Ltd 
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INTRODUCTION 
Asthma is a chronic inflammatory disorder of the air- 
ways, which arises from a complex interaction of many 
cells, such as eosinophils, mast cells and T lymphocytes 
(1,2). The inflammatory nature of the disease forms the 
basis for the bronchial hyper-responsiveness and symp- 
toms of the disorder. Asthma may develop at any time 
during a person’s life and involves between 5 and 10% of 
adults (3). Despite awareness of the inflammatory nature 
of the disease and the established role of inhaled corti- 
costeroids (KS), asthma incidence and the morbidity 
and mortality remain unacceptably high (1,2,4). 
Several national guidelines have been developed in an 
attempt to improve asthma care. These guidelines such 
as the one from the National Institutes of Health (NIH) 
recommend ICS as the most effective long-term anti- 
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inflammatory treatment for all grades of asthma severity 
(1,5). A stepwise approach to drug treatment with esca- 
lating doses of ICS commensurate with the asthma sever- 
ity is recommended. Likewise step-up or step-down of 
treatment is suggested depending on the control 
achieved. The main goals of asthma treatment are main- 
tenance of normal pulmonary function, normal activity 
levels, prevention of troublesome symptoms, prevention 
of exacerbations, and the provision of drugs with mini- 
mal side-effects (I). 
Short-acting /!&,-agonists are prescribed on an ‘as 
needed’ basis for the acute relief of symptoms. If asthma 
is not well controlled or short-acting /Iz-agonists are 
used too frequently then there is a need to increase the 
dose of ICS or add a long-acting b2-agonist. The combi- 
nation of an ICS and a long-acting Pz-agonist is more 
effective at improving lung function and symptoms than 
increasing the dose of ICS (6,7). 
One of the obstacles to optimizing asthma control in 
the population is poor adherence to prescribed treat- 
ment. The reasons for poor adherence include: a) the 
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negative perception of KS; b) failure to understand the 
need for continued medication after symptomatic im- 
provement; c) poor inhaler technique; and d) compli- 
cated treatment regimens (5). Patient education is vital 
in achieving the goals of asthma treatment and improving 
adherence to treatment (I). Prescribing a long-acting fiz- 
agonist and an ICS in separate inhalers complicates treat- 
ment and contributes to non-adherence. Thus the avail- 
ability of ICS and long-acting Pa-agonists in a single 
inhaler should improve adherence. 
Symbicort@ is a new treatment that combines the 
ICS, budesonide, and the long-acting PI-agonist, formo- 
terol in a single Turbuhaler? a dry powder inhaler de- 
vice. The efficacy and safety of the individual 
components are well established. This article describes 
the rationale behind the combination of ICS with long- 
acting Pz-agonists and reviews the experience to date 
with Symbicort@ In the treatment of adults with asthma. 
EFFICACY OF BUDESONIDE AND 
FORMOTEROL 
Inhaled budesonide is a well-established ICS in the man- 
agement of chronic persistent asthma. Its high ratio of 
local anti-inflammatory to systemic activity allows thera- 
peutically effective doses to be administered with mini- 
mized systemic effects (8,9). As with other ICS, very high 
doses of budesonide increase the riskof systemic side-ef- 
fects (IO) and the lowest effective dose of ICS should be 
used to achieve asthma control.The optimal dose of bu- 
desonide for moderate persistent asthma administered 
via theTurbuhaler@ is between 400 and 8OOpg day-’ (I). 
A 6-month study in 213 patients with moderate asthma 
demonstrated that good control could be achieved 
with a lower dose of budesonide (200 pg day-‘) together 
with short courses of higher doses of budesonide 
(800 pg day-‘) (II). Budesonide administered by the Tur- 
buhaler@ is considered to be approximately equipotent 
to fluticasone propionate by DiskhalerTM (8) and has been 
demonstrated to have less adrenal suppression (10,12,13). 
Inhaled ICS reduce inflammation as well as bronchial 
hyper-responsiveness in asthma (14). Budesonide has 
been shown to protect against bronchial hyper-respon- 
siveness for up to 3 months following withdrawal of 
treatment (15). In addition, exercise-induced broncho- 
constriction which occurs in about 70-80% of asth- 
matics can be prevented by 3-6 weeks of treatment 
with budesonide (9,16). 
Patients not adequately controlled with low-dose ICS 
require step-up in treatment. Several therapeutic op- 
tions are available and these include increasing the dose 
of ICS or adding a long-acting &-agonist. Several well- 
controlled trials have indicated that the latter comb- 
ination offers better symptom control and improvement 
in lung function than increasing the dose of ICS (6,717). 
Formoterol is a selective flz-receptor agonist that has a 
duration of action of approximately I2 hours when admin- 
istered by the inhaled route. This compares well with a 
similar duration of action of short-acting /Iz-agonists ad- 
ministered orally (18). Like salmeterol, formoterol im- 
proves lung function and controls asthma symptoms 
such as nocturnal and exercise-induced asthma symp- 
toms (19,20). However, in contrast to salmeterol, formo- 
terol has a rapid onset of action similar to that observed 
with short-acting bz-agonists (21,22). 
Formoterol has also been demonstrated to be safe at 
doses equivalent to and higher than those recommended 
for maintenance treatment (23-26). Daily doses of for- 
moterol up to 90 ,ug delivered dose have been shown to 
be safe and well tolerated in patients with chronic asthma 
(25). In contrast to salmeterol, formoterol also has a 
wide therapeutic window and has a tolerability profile 
comparable with short-acting /3z-agonists such as salbu- 
tamol and terbutaline and can be used as needed (27). 
The long-term efficacy and tolerability of formoterol 
has been reported for periods of up to 5 years without 
evidence of reduced response or diminished asthma con- 
trol (23). 
CONCURRENT USE OF BUDESONIDE 
AND FORMOTEROL 
In a l-year randomized, controlled trial, Pauwelsetal. dem- 
onstrated convincingly that the addition of formoterol to 
inhaled budesonide was superior to increased doses of 
budesonide (17). At baseline, 852 adult patients (18-70 
years old) received budesonide 400,~g twice daily for 
4 weeks. They were then randomized to receive twice- 
daily treatment with: 100 pg of budesonide; 100 pg of bu- 
desonide plus I2 ,ug of formoterol; 400 pg of budesonide; 
or 400,~g of budesonide plus l2,~g of formoterol for I2 
months.The rates of severe and mild exacerbations were 
reduced when formoterol was added to the lower dose 
of budesonide.The greatest reduction was achieved with 
the higher dose of budesonide plus formoterol.The com- 
bination of budesonide (IOOpg or 4OOpg) plus formo- 
terol (I2 pg) produced a greater improvement in forced 
expiratory volume in one second (FEV, ) compared with 
the higher and lower dose of budesonide treatment 
alone.These findings confirmed that in subjects with per- 
sistent asthma the addition of formoterol improves 
symptoms and lung function and reduces exacerbation 
rates. 
The concern relating to the addition of long-acting pz- 
agonists to ICS compared with increasing the dose of ICS 
is that the underlying inflammation may be masked and 
this may predispose to a more severe exacerbation. The 
study by Pauwels et al., described above, clearly demon- 
strated that exacerbation rates were reduced with the 
addition of formoterol to budesonide (17). A recent study 
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used eosinophils in induced sputum as a marker of airway 
inflammation and compared low-dose budesonide 
(lOO,ug twice daily) and formoterol (l2pg twice daily) to 
a higher dose of budesonide (4OOpg twice daily). There 
was a 4-week run-in period during which time all pa- 
tients received high-dose budesonide alone, after which 
they were randomized to combination treatment (low- 
dose budesonide and formoterol) and high-dose budeson- 
ide alone (28). There was no difference in sputum 
eosinophils in either group. Several other studies have 
confirmed that the addition of a long-acting /Iz-agonist 
does not compromise asthma control (6,729). 
Therefore, the addition of a long-acting /&-agonist in 
preference to increasing the dose of ICS in ‘stepping-up’ 
treatment has been shown to be beneficial without com- 
promising asthma control in terms of: a) symptoms; b) 
lung function; and c) airway inflammation. We may also 
conclude that level A evidence (randomized control trials 
and a rich body of evidence) exists for the recommen- 
dation that the addition of a long-acting /&-agonist is pref- 
erable to increasing the dose of ICS in ‘stepping-up’ 
asthma treatment. In this context the combination of 
formoterol and budesonide appears to be beneficial and 
the development of a singleTurbuhaler inhaler combining 
these drugs was a logical progression. 
SYMBICORT@ CONTROLLING 
ASTHMA IN ADULTS 
Symbicort @ Turbuhaler @ is a dry powder inhaler con- 
taining both budesonide and formoterol. Here we report 
the efficacy and safety of Symbicort@ in two l2-week, 
multicentre, multinational, double-blind studies involving 
over 800 patients (30,31). 
In the first of these studies (Study I) Symbicort@ (bu- 
desonide/formoterol 160/4*5pg; a dose of two inha- 
lations twice daily (b.d.)) was compared with an equiva- 
lent dose of budesonide and formoterol given via sepa- 
rate inhalers and budesonide (4OOpg b.d.) monotherapy 
(Table I). In the second study (Study 2) Symbicort@ (bu- 
desonide/formoterol 80/4*5 pug; one inhalation b.d.) was 
compared with budesonide (200 pg b.d.) monotherapy 
(Table I). The doses of budesonide in the Symbicort@ 
preparation were measured as delivered dose and were 
equivalent to the metered dose of budesonide admin- 
istered via separate inhaler. 
At baseline, patients were not fully controlled on a 
mean daily dose of approximately 400,ug ICS (31) and 
lOOO,ug ICS daily (30) (Table I). All patients had experi- 
enced asthma for at least I2 years, had a low number of 
symptom-free days and the mean FEV, was on average 
73-82% of the predicted normal, with approximately 
22% reversibility. 
Lung function was assessed in terms of peak expira- 
tory flow (PEF), FEVr and forced vital capacity (FVC) as 
an objective measure of treatment efficacy. Other out- 
come measures included use of reliever medication, total 
asthma symptom scores, nocturnal awakenings, symp- 
tom-free days and asthma-control days. Chdnge in use 
of reliever medication was also assesse<:. 
Symbicort@ is significantly more effective 
than budesonide alone 
In both studies, considerable improvements in lung func- 
tion and outcome measures were observed in those 
patients who received I2 weeks’ treatment with 
SymbicortO compared with baselinevalues.The morning 
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0 Morning PEF 
Evening PEF 
Study 1 Study 2 
*P= 0.002; **P<O.OOl - Symbicort 8 vs budesonide 
Figure I. Between-group difference in morning and evening 
PEFfollowing 12 weelcs’treatment with Symbicort@or budeson- 
ide alone in two studies (Study I: Symbicort” (budesonide/for- 
moterol 160/4.5 pg, two inhalations twice daily (b.d.)) vs budeso- 
nide 2OOblg, two inhalations b.d.; Study 2: Symbicort@ 
(budesonide/formoterol 80/4.5 pg b.d.) vs budesonide 200 fig 
b. d.), 
and evening PEF increased to a significantly greater ex- 
tent in Symbicort@ patients than in those with budeson- 
ide monotherapy (Figure I). In Study I improvements 
were demonstrated in FEV, for Symbicort@ (budeson- 
ide/formoterol l60/4.5 pg; two inhalations b.d.) com- 
pared with budesonide alone (400,ug b.d.). In Study 2 
statistically significant improvements in lung function 
were seen after Symbicort@ treatment compared with 
the group that received a two-fold increase in budeson- 
ide. Symbicort@ was more effective than budesonide 
monotherapy in improving all individual outcomes 
measured in both studies (Table 2a and b). The total 
asthma symptom scores were lower in the Symbicort@ 
group compared with budesonide monotherapy in both 
studies, the difference being statistically significant 
(P<O.OOl) in Study I. The proportion of symptom-free 
days was significantly (P<O.Ol) improved in both studies 
with Symbicort@ compared with budesonide monother- 
spy. Furthermore, the number of days when reliever 
medication was not required was significantly greater 
(P<O.OOl) during Symbicort@ treatment than with bu- 
desonide alone.These results were reflected in the com- 
posite outcomes measure of asthma-control days 
defined as no asthma symptoms, no use of reliever medi- 
cation and no nocturnal awakening. In both studies, Sym- 
bicort@ treatment achieved significantly (P< 0.01) more 
asthma-control days compared with budesonide mono- 
therapy (Figure 2). Overall these results clearly dem- 
onstrate the significant improvement achieved with Sym- 
bicort” in adults who are poorly controlled on ICS alone 
and confirm the advantage of adding formoterol to low- 
dose budesonide compared with doubling the dose of bu- 
desonide. 
Symbicort@ is as effective as budesonide plus 
formoterol administered separately 
An additional concern is that a physico-chemical interac- 
tion may occur by combining two complex molecules 
into one inhaler device. SymbicortO has been shown to 
retain the advantage gained by the addition of formo- 
terol over doubling the dose of budesonide as demon- 
strated by Pauwels et al. (17). When Symbicort@ treat- 
ment was compared with budesonide and formoterol 
administered separately (30) there was no statistically 
significant difference with respect to: morning and even- 
ing PEF, total asthma symptom scores, symptom-free 
days, days when no reliever medication was used and re- 
liever medication usage. Thus, Symbicort@) retains the 
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Study 1 Study 2 
*:p = 0.002; **P < 0.001 - Symbicort@ vs budesonide 
Figure 2. Between-group difference in asthma-control days 
following 12 weelcs’treatment with Symbicort@ or budesonide 
alone in two studies (Study I: Symbicort@ (budesonide/formo- 
terol 160/4.5 pg, two inhalations twice daily (b.d.)) vs budesonide 
20O,~g, two inhalations b.d.; Study 2: Symbicort@ (budesonide/ 
formoterol 80/4.5 pg b.d.) vs budesonide 2OOpg b.d.). 
efkacy of the two individual drug components, but has 
the added advantages of being administered in a single, 
easy-to-use inhaler that can be used at a range of doses. 
Symbicort@ is well tolerated 
Safety and tolerability were assessed in a total of 353 
patients who received Symbicort@, II5 who received 
budesonide and formoterol and 361 who received bude- 
sonide monotherapy. Symbicort@ was well tolerated and 
the adverse event profile was similar across all treatment 
groups (Figures 3a and b).The most commonly reported 
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Figure 3. Most frequently reported adverse events in two 12. 
weelc multinational studies. (a) Study I: Symbicort@ (budeson- 
ide/formoterol 160/4.5 pg: two inhalations, twice daily (b.d.)) vs 
budesonide + formoterol (200 pg + 4.5 pg, respectively; two 
inhalations, b.d.) vs budesonide 2OOpg, two inhalations b.d.; (b) 
Study 2: Symbicort@ (budesonide/formoterol 80/4.5 pg b.d.) vs 
budesonide 200 pg b.d. 
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adverse event was respiratory infection. Discontinu- 
ations due to adverse events (including worsening of 
asthma) occurred at a similar rate in all treatment 
groups. Undesirable &agonist class effects, such as tre- 
mor and palpitations, were seen with a similar low fre- 
quency (12% of patients) in all groups. Undesirable 
inhaled corticosteroid class effects, such as dysphonia 
and oral candidiasis, were also rare and no pattern of 
events was observed to indicate systemic effects. Symbi- 
tort@ (budesonide/ formoterol 160/4.5 ,ug; two inhala- 
tions b.d.) was as equally well tolerated as Symbicort@ 
(budesonide/formoterol 80/4.5 pg b.d.) indicating that it 
is safe to increase the dose of budesonide and formoterol 
if asthma control is lost due to an increase in asthma 
severity. 
CONCLUSION 
Modern asthma guidelines recommend the addition of a 
long-acting /&agonist when asthma is not controlled on 
low-dose ICS. Level A evidence is available for this rec- 
ommendation. Symbicort@ has proved to be significantly 
more effective than budesonide monotherapy in patients 
whose asthma is not fully controlled on ICS therapy. Ad- 
ministration of Symbicorta is as effective and well toler- 
ated as concurrent but separate administration of the 
two active agents, budesonide and formoterol. Symbi- 
tort@ appears to offer the flexibility required to appro- 
priately manage the variability in asthma severity seen in 
the clinical setting. Symbicort@ in its easy to use formu- 
lation and inhaler device represents avaluable addition to 
the pharmacological management of asthma. The bene- 
fits of Symbicort@ are being investigated further in on- 
going clinical trials. 
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